Tasly: ​​The pharmaceutical group controls Yunnan Maye Biotechnology Co., Ltd. through Tianhua Jinjian, a subsidiary of a listed company_ Oriental Fortune Net

Every time the AI ​​Express is sent, some investors ask questions on the investor interaction platform:TaslyThe capital injection of Puyuan Miaosheng’s 500 million yuan Yunnan hemp leaf project is used for industrial hemp. What is the follow-up progress? Does it provide a new profit growth point for the company? What is the prospect of the Yunnan hemp project, and will the investment in Yunnan hemp industry be increased in the future?TaslyPharma Group and Hong Kong stock Meirui Health become the second largest Chinese Hemp Groupshareholder, what is the annual return on investment?rightTaslyperformanceHow much is the boost?Will China Hemp Group Backdoor Tasly Assets?reorganizationOptimizing listing?thanks

Tasly (600535.SH) stated on the investor interaction platform on April 4 that the pharmaceutical group controlled Yunnan Maye Biotechnology Co., Ltd. through Tianhua Jinjian, which is the grandson of 600535. The company is currently optimizing the process of industrial hemp full-spectrum oil. , to explore the diverse applications of industrial hemp in the field of medicine and medicine.The relevant R&D business is still in the early stage, and the follow-up company will continue to promote related work. For relevant information, please refer to the company’s follow-upannouncementprevail.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 3

Original title: Tasly: ​​The pharmaceutical group holds Yunnan Maye Biotechnology Co., Ltd. through Tianhua Jinjian, which is the grandson of the listed company